Compare SABS & OIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SABS | OIA |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.9M | 281.8M |
| IPO Year | 2020 | 1994 |
| Metric | SABS | OIA |
|---|---|---|
| Price | $2.85 | $5.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $11.64 | N/A |
| AVG Volume (30 Days) | ★ 684.9K | 179.0K |
| Earning Date | 11-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 78.53 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.44 | $5.09 |
| 52 Week High | $5.15 | $6.40 |
| Indicator | SABS | OIA |
|---|---|---|
| Relative Strength Index (RSI) | 43.62 | 27.73 |
| Support Level | $2.44 | $5.09 |
| Resistance Level | $4.03 | $6.26 |
| Average True Range (ATR) | 0.26 | 0.11 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 37.58 | 3.20 |
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
Invesco Municipal Income Opportunities Trust is a closed-end management investment company. The Trust's investment objective is to provide a high level of current income which is exempt from federal income tax.